NRP1 and prostate carcinoma: In a prostate cancer model, transfection of NRP-1 increased VEGF165 binding, basal cell motility, and tumour size in vivo (Miao et al, 2000), suggesting that the receptor functions in a VEGF-dependent fashion to enhance tumorigenicity.